Analysts Set Cellebrite DI Ltd. (NASDAQ:CLBT) PT at $22.50

Shares of Cellebrite DI Ltd. (NASDAQ:CLBT) have received a consensus rating of “Moderate Buy” from the five research firms that are presently covering the company, Marketbeat Ratings reports. One analyst has rated the stock with a sell rating and four have issued a buy rating on the company. The average 1-year price target among analysts that have issued a report on the stock in the last year is $22.50.

CLBT has been the subject of a number of analyst reports. Wall Street Zen raised Cellebrite DI from a “sell” rating to a “hold” rating in a report on Sunday, March 15th. Needham & Company LLC cut their price target on Cellebrite DI from $24.00 to $18.00 and set a “buy” rating for the company in a report on Thursday, February 12th.

Cellebrite DI Price Performance

NASDAQ:CLBT opened at $13.32 on Monday. The business has a fifty day simple moving average of $13.57 and a two-hundred day simple moving average of $15.85. Cellebrite DI has a 1 year low of $11.02 and a 1 year high of $20.53. The company has a market capitalization of $3.32 billion, a P/E ratio of 42.98, a P/E/G ratio of 2.05 and a beta of 1.15.

Cellebrite DI (NASDAQ:CLBT) last released its earnings results on Wednesday, February 11th. The company reported $0.14 earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of $0.14. Cellebrite DI had a return on equity of 20.43% and a net margin of 16.47%.The business had revenue of $128.82 million during the quarter, compared to the consensus estimate of $126.07 million. During the same period last year, the business posted $0.10 earnings per share. The business’s revenue for the quarter was up 28.8% on a year-over-year basis. As a group, analysts anticipate that Cellebrite DI will post 0.43 earnings per share for the current year.

Hedge Funds Weigh In On Cellebrite DI

A number of large investors have recently made changes to their positions in the stock. Venturi Wealth Management LLC boosted its holdings in shares of Cellebrite DI by 5.0% in the third quarter. Venturi Wealth Management LLC now owns 14,700 shares of the company’s stock worth $272,000 after acquiring an additional 700 shares during the period. CWM LLC boosted its holdings in shares of Cellebrite DI by 85.7% in the third quarter. CWM LLC now owns 1,560 shares of the company’s stock worth $29,000 after acquiring an additional 720 shares during the period. Towarzystwo Funduszy Inwestycyjnych PZU SA boosted its stake in Cellebrite DI by 81.0% during the fourth quarter. Towarzystwo Funduszy Inwestycyjnych PZU SA now owns 1,900 shares of the company’s stock valued at $34,000 after buying an additional 850 shares during the period. Blue Trust Inc. boosted its stake in Cellebrite DI by 4.0% during the third quarter. Blue Trust Inc. now owns 23,121 shares of the company’s stock valued at $428,000 after buying an additional 898 shares during the period. Finally, SkyView Investment Advisors LLC boosted its stake in Cellebrite DI by 2.6% during the second quarter. SkyView Investment Advisors LLC now owns 37,708 shares of the company’s stock valued at $597,000 after buying an additional 970 shares during the period. 45.88% of the stock is owned by institutional investors.

Cellebrite DI Company Profile

Cellebrite DI is a global provider of digital intelligence and forensics solutions that enable law enforcement agencies, government bodies and enterprises to extract, analyze and act on data from mobile devices, cloud services and digital sources. The company’s technology is designed to accelerate investigations, support evidence-based decision-making and enhance security operations by delivering actionable intelligence in a secure, scalable platform.

The company’s flagship offerings include the Universal Forensic Extraction Device (UFED) series for data acquisition and decoding, Physical Analyzer for advanced data parsing and visualization, and Pathfinder for case-driven investigation workflows.